The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Lung cancer is the leading cause of cancer‐related deaths worldwide. Non‐small cell lung cancer (NSCLC) accounts for nearly 85% of all lung cancer and includes adenocarcinoma, squamous cell carcinoma and large cell carcinoma histology. Treatment of NSCLC is based on stage at the time of diagnosis, histological subtype, molecular status and performance status of the patient. Treatments for early‐stage...
The discovery of “driver” genomic alterations in patients with non‐small cell lung cancer (NSCLC) has dramatically changed the field of thoracic oncology in recent years. The best understood of these molecular drivers are those involving the epidermal growth factor receptor (EGFR), which when aberrantly activated are integral to the development of a subset of NSCLC tumors. First‐generation and second‐generation...
BACKGROUNDEpigenetic events play a major role in the carcinogenesis of tobacco‐related cancers. The authors conducted a retrospective cohort study to evaluate the effects of exposure to the anticonvulsant agent valproic acid (VPA), a histone deacetylase inhibitor, on the risk of developing cancers of the lung, head and neck, prostate, bladder, and colon.
METHODSThe study was based on the 2002 through...
BACKGROUNDThis phase 2 trial (ClinicalTrials.gov identifier NCT00548093) assessed the efficacy, safety, and impact on health‐related quality of life of dacomitinib (PF‐00299804), an irreversible tyrosine kinase inhibitor (TKI) of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, in patients with KRAS wild‐type non–small cell lung cancer (NSCLC).
METHODSPatients with advanced NSCLC,...
BACKGROUND:Reliable predictive biomarkers are required to address the challenge of disease recurrence after thyroid cancer surgery. For this study, the authors assessed the association of cellular‐based and serum‐based immunologic mediators with thyroid cancer recurrence.
METHODS:Leukocyte subset counts and immune regulatory cytokine levels were determined in peripheral blood samples using multiparameter...
ObjectiveWe examined correlates of continued smoking versus cessation among a sample of survivors of smoking‐related cancers who were actively smoking at the time of cancer diagnosis.
MethodsParticipants with a history of smoking and a smoking‐related cancer diagnosis (lung, oral, pharynx, larynx, esophagus, bladder, stomach, cervix, kidney, pancreas, acute myeloid leukemia) within the past 4 years...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.